See how Eli Lilly and Company and Tesla, Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$1,179.11
NYSE
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.
Tesla, Inc. is a vertically integrated battery electric vehicle manufacturer and developer of real-world artificial intelligence software, including autonomous driving technology and humanoid robots. Its vehicle lineup includes luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to launch a sports car and introduce a robotaxi service. In 2025, the company delivered nearly 1.64 million vehicles globally. Beyond automotive operations, Tesla sells batteries for stationary energy storage across residential, commercial, and utility applications, along with solar panels and solar roofs for power generation. The company also operates a fast-charging network and an auto insurance business.